Neurocognitive Disorder clinical trials at UCLA
2 in progress, 0 open to eligible people
Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
Sorry, not yet accepting patients
A phase II, randomized, open-label, two-arm clinical trial evaluating the safety and efficacy of pramipexole extended release (ER) versus escitalopram for the treatment of major depressive disorder (MDD) and comorbid MDD with mild neurocognitive disorder (MND) in persons with HIV (PWH). Participants will be assessed comprehensively and briefly at intercurrent visits to monitor for toxicity, response to therapy, and to assess for dose changes. An optional sub-study to evaluate treatment impact on the cerebrospinal fluid (CSF) profile will be conducted in a subset of 36 participants.
Los Angeles 5368361, California 5332921 and other locations
Innovative Support for Patients With SARS-COV2 Infections (COVID-19) Registry (INSPIRE)
Sorry, in progress, not accepting new patients
The Innovative Support for Patients with SARS COV-2 Infections Registry (INSPIRE) study is a CDC-funded COVID-19 project to understand the long-term health outcomes in recently tested adults, both negative and positive, who have suspected COVID symptoms at the time of their test. Participants will complete short online surveys every 3 months for 18 months, share information about their health using a secure web-based platform, and are compensated for their time.
Los Angeles 5368361, California 5332921 and other locations
Our lead scientists for Neurocognitive Disorder research studies include Kara Chew, MD, MS.
Last updated: